FLASCO

FLASCO News

Home » Current News & Publications » FLASCO News

Boehringer Ingelheim Patient Assistance Program

Boehringer Ingelheim is on a mission to improve lives around the world. We do this by developing innovative medicines and helping patients gain access to them – wherever they may be – and by supporting innovative programs that help ensure the health of individuals and communities in this and future generations.

FDA Approves Mogamulizumab-kpkc for Two Rare Types of Non-Hodgkin Lymphoma

U.S. Food and Drug Administration approved mogamulizumab-kpkc (Poteligeo) injection for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy. This approval provides a new treatment option for patients with mycosis fungoides and is the first FDA approval of a drug specifically...

Florida Cancer Specialists & Research Institute Welcomes Dr. Simon Abi Aad

New Medical Oncologist Joins in Naples Naples, FL – August 6th, 2018. . . Florida Cancer Specialists & Research Institute (FCS), the largest community oncology/hematology practice in the state, is pleased to announce that medical oncologist Simon Abi Aad, MD, has joined the statewide practice and will be practicing at the Naples Napa Ridge office, located at 6360 Pine Ridge Road,...

FDA Approves Iobenguane I-131 for Rare Adrenal Gland Tumors

On July 30, the U.S. Food and Drug Administration (FDA) approved iobenguane I-131 (Azedra) injection for adult and pediatric patients (12 years and older) with iobenguane scan–positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (PPGL) who require systemic anticancer therapy. “Many patients with these ultra-rare cancers can be treated with surgery or local therapies, but there...

Shionogi & Co Ltd’s treatment for low blood-platelet count or thrombocytopenia in patients with chronic liver disease approved by FDA

On July 31, 2018, the Food and Drug Administration approved lusutrombopag (Mulpleta, Shionogi Inc.) for thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. Approval was based on two randomized, double-blind, placebo-controlled trials (L-PLUS 1 and L-PLUS 2, NCT02389621) involving 312 patients with chronic liver disease and...

FDA Discontinues Iclusig® REMS Program

FLASCO has been notified that Takeda Oncology was recently advised by the U.S. Food and Drug Administration (FDA) that the REMS (Risk Evaluation and Mitigation Strategy) communication plan for ICLUSIG® (ponatinib) is no longer required. After a comprehensive assessment, FDA determined the ICLUSIG REMS communication plan had met its goals. As a result, the REMS...

FDA approves magnetic device system for guiding sentinel lymph node biopsies in certain patients with breast cancer

The U.S. Food and Drug Administration  approved a magnetic device system for guiding lymph node biopsies in patients with breast cancer undergoing mastectomy. The Magtrace and Sentimag Magnetic Localization System (Sentimag System) uses magnetic detection during sentinel lymph node biopsy procedures to identify specific lymph nodes, known as sentinel lymph nodes, for surgical removal. “Sentinel...

pfizer

FDA approves Nivestym (filgrastim-aafi) a biosimilar to Neupogen (filgrastim)

The FDA approved Nivestym (filgrastim-aafi), a biosimilar to Neupogen (filgrastim). This is the second approved biosimilar to Neupogen approved in the U.S. Click to read the Pfizer Press Release >> Nivestym Press Release Nivestym is approved for the same indications as Neupogen, and can be prescribed by a health care professional for: •       patients...

FDA Releases Biosimilars Action Plan

FDA released the Biosimilars Action Plan (BAP) to provide information about the key actions the agency is taking to encourage innovation and competition among biologics and the development of biosimilars.   The BAP is focused on four key areas: improving the efficiency of the biosimilar and interchangeable product development and approval process; maximizing scientific and...

agios pharma

FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation

The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. This is the first drug in its class (IDH1 inhibitors) and is approved for use with an FDA-approved companion diagnostic used to detect specific...

Cancer Groups Object to Medicare Proposals to Cut Part B

Cancer Groups Object to Medicare Proposals to Cut Part B Source: Medscape – Kerry Dooley Young – July 19, 2018 Oncology groups are opposed to some of the proposals currently under consideration in the United States that are aimed at reducing the high cost of drugs. In recent years, a flood of new cancer drugs has...

XTANDI Significantly Extended Metastasis-Free Survival in Patients with Nonmetastatic CRPC

Astellas Pharma US, Inc. and Pfizer Inc. are pleased to announce that XTANDI is now indicated for the treatment of patients with CRPC.1 PROSPER was a multinational, randomized, double-blind, placebo-controlled phase 3 study of XTANDI + LHRH therapy† in patients with nonmetastatic CRPC who had progressed on LHRH therapy.†1,2 In PROSPER, 1401 patients with nonmetastatic...

FDA expands ribociclib indication in HR-positive, HER2-negative advanced or metastatic breast cancer

On July 18, 2018, the Food and Drug Administration expanded the indication for ribociclib (Kisqali, Novartis Pharmaceuticals Corporation) in combination with an aromatase inhibitor for pre/perimenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy. FDA also approved ribociclib in combination with fulvestrant for postmenopausal women with HR-positive, HER2-negative advanced or...

FLASCO Donates $20,000 to Provide Scholarships for University of Puerto Rico School of Medicine First Year Students for a Summer Research Fellowship in Cancer Research at Mayo Clinic Cancer Center Jacksonville, Fl in Summer 2018. 

FLASCO donated $20,000 to provide 4 scholarships for University of Puerto Rico School of Medicine First Year Students a Summer Research Fellowship in Cancer Research at Mayo Clinic Cancer Center Jacksonville, Fl in Summer 2018. This program, originally funded by the NIH CCATS grant, consists of a week long course on research given by faculty...

FDA Approves enzalutamide for castration-resistant prostate cancer

On July 13, 2018, the Food and Drug Administration approved enzalutamide (XTANDI, Astellas Pharma US, Inc.), for patients with castration-resistant prostate cancer (CRPC). This approval broadens the indicated patient population to include patients with both non-metastatic CRPC (NM-CRPC) and metastatic CRPC. Enzalutamide was previously approved for the treatment of patients with metastatic CRPC. Approval in...

FDA grants accelerated approval to ipilimumab for MSI-H or dMMR metastatic colorectal cancer

On July 10, 2018, the Food and Drug Administration granted accelerated approval to ipilimumab (YERVOY®, Bristol-Myers Squibb Company Inc.) for use in combination with nivolumab for the treatment of patients 12 years of age and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with...

FDA limits the use of Tecentriq and Keytruda for some urothelial cancer patients

FDA has limited the use of Tecentriq and Keytruda for patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing therapy. The Agency took this action on June 19, 2018, due to decreased survival associated with the use of Keytruda (pembrolizumab) or Tecentriq (atezolizumab) as single therapy (monotherapy) compared to platinum-based...

FDA Approves ZEMDRI (plazomicin) for the Treatment of Patients with Complicated Urinary Tract Infections Including Pyelonephritis

On June 25, 2018, the U.S. Food and Drug Administration (FDA) approved ZEMDRI (plazomicin) for the treatment of patients 18 years of age or older with complicated urinary tract infections (cUTI) including pyelonephritis. As only limited clinical safety and efficacy data are available, reserve ZEMDRI for use in patients who have limited or no alternative...

FDA approves encorafenib and binimetinib in combination for unresectable or metastatic melanoma with BRAF mutations

On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. Approval was based on a randomized, active-controlled, open-label, multicenter trial (COLUMBUS; NCT01909453) in 577...

FLASCO Member Selected to be a Part of the ASCO 2018-2019 Leadership Development Program

Congratulations are in order for FLASCO member,  Dr. Nathalie McKenzie, for being selected to be a part of the ASCO 2018-2019 Leadership Development Program.  We are proud to have Dr. McKenzie represent FLASCO and the great state of Florida! Nathalie Dauphin McKenzie, MD, MSPH Florida Hospital Cancer Institute Nathalie Dauphin Mckenzie, MD, MSPH, serves as Director of...

FDA approves pembrolizumab for treatment of relapsed or refractory PMBCL

On June 13, 2018, the Food and Drug Administration granted accelerated approval to pembrolizumab (Keytruda, Merck) for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after two or more prior lines of therapy. Approval was based on data from 53 patients with relapsed or...

New indication for VENCLEXTA(R) (venetoclax tablets)

On June 8, 2018, VENCLEXTA® (venetoclax tablets) was approved by the US Food and Drug Administration (FDA) for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. Genentech BioOncology® Access Solutions is your resource for access and...

UF Health

UF Health Cancer Center Navigator Referring Physician Resource

Connect with the UF Health Cancer Center Stay in the know. See what the UF Health Cancer Center is doing when you sign up to receive news and updates, information about current clinical trials, our magazine and our annual report. View full newsletter here. Subscribe to Cancer Center News here.

FDA approves bevacizumab for ovarian cancer and pembrolizumab for large B-cell lymphoma cancer

Bevacizumab for Ovarian Cancer On June 13, 2018, the Food and Drug Administration approved bevacizumab (Avastin®, Genentech, Inc.) for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, for stage III or IV disease after initial surgical resection. Approval was based on GOG-0218 (NCT00262847),...

FDA Approves New Treatment for Women with Advanced Ovarian Cancer After Initial Surgery

Today, the FDA granted approval to Avastin in combination with chemotherapy, followed by Avastin alone, for the treatment of women with advanced (stage III or IV) ovarian cancer after initial surgery. The Genentech press release including Important Safety Information is linked here. This approval marks an important milestone in ovarian cancer, as this is the...

Who’s Online

There are no users currently online